SAN DIEGO, Sept. 2, 2020 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr.
Helen Torley, president and chief
executive officer, will participate in the upcoming 2020 Wells
Fargo Virtual Healthcare Conference. Dr. Torley will take part in a
fireside chat at 10:00 a.m. ET /
07:00 a.m. PT on Wednesday, September 9,
2020.
A live webcast of the event can be accessed through the
"Investors" section of Halozyme's website (www.halozyme.com), and
an archive will be made available for 90 days following the event.
To access a live webcast, please visit Halozyme's website
approximately 15 minutes prior to the presentation to register and
download any necessary audio software.
About Halozyme
Halozyme is a biopharmaceutical company bringing disruptive
solutions to significantly improve patient experiences and outcomes
for emerging and established therapies. Halozyme advises and
supports its biopharmaceutical partners in key aspects of new drug
development with the goal of improving patients' lives while
helping its partners achieve global commercial success. As the
innovators of the ENHANZE® technology, which can reduce
hours-long treatments to a matter of minutes, Halozyme's
commercially-validated solution has positively impacted more than
400,000 patient lives via five commercialized products across more
than 100 global markets. Halozyme and its world-class partners are
currently advancing multiple therapeutic programs intended to
deliver innovative therapies, with the potential to improve the
lives of patients around the globe. Halozyme's proprietary
recombinant human hyaluronidase enzyme rHuPH20 forms the basis of
the ENHANZE® drug delivery technology and is used to
facilitate the subcutaneous delivery of injected drugs and fluids,
potentially reducing the treatment burden of other drugs to
patients. Halozyme has licensed its ENHANZE® drug
delivery technology to leading pharmaceutical and biotechnology
companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly,
Bristol-Myers Squibb, Alexion and argenx. Halozyme derives revenues
from these collaborations in the form of milestones and royalties
as the Company's partners make progress developing and
commercializing their products being developed with
ENHANZE®. Halozyme is headquartered in San Diego. For more information visit
www.halozyme.com.
Contact:
Al Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/halozyme-to-participate-in-2020-wells-fargo-virtual-healthcare-conference-301123227.html
SOURCE Halozyme Therapeutics, Inc.